Terms: = Lung cancer AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Treatment
33963 results:
1. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Yin X; Liu X; Ren F; Meng X
Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
[TBL] [Abstract] [Full Text] [Related]
2. Identification and analysis of prognostic immune cell homeostasis characteristics in lung adenocarcinoma.
Sun Y; Ma Q; Chen Y; Liao D; Kong F
Clin Respir J; 2024 May; 18(5):e13755. PubMed ID: 38757752
[TBL] [Abstract] [Full Text] [Related]
3. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract] [Full Text] [Related]
4. Clinic information, pathological, and imaging characteristics in 2 058 surgical patients with lung cancer from a single center.
Long B; Xiong Z; Liu S; Cheng Y; Li M; Liao W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):247-255. PubMed ID: 38755720
[TBL] [Abstract] [Full Text] [Related]
5. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell lung cancer.
Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
[TBL] [Abstract] [Full Text] [Related]
6. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
7. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM
PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of sex inequity in lung-cancer-specific survival.
Lærum D; Strand TE; Brustugun OT; Gallefoss F; Falk R; Durheim MT; Fjellbirkeland L
Acta Oncol; 2024 May; 63():343-350. PubMed ID: 38751329
[TBL] [Abstract] [Full Text] [Related]
9. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
[TBL] [Abstract] [Full Text] [Related]
10. Development of a novel laboratory photodynamic therapy device: automated multi-mode LED system for optimum well-plate irradiation.
Yildiz MZ; Kamanli AF; Eskiler GG; Tabakoğlu HÖ; Pala MA; Özdemir AE
Lasers Med Sci; 2024 May; 39(1):131. PubMed ID: 38750381
[TBL] [Abstract] [Full Text] [Related]
11. Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Bang AS; Said JT; Hirner J; Rana J; Pugliese S; Wang JY; Zaba L; Zhao L; Doan L; Smith J; Kwong BY
Support Care Cancer; 2024 May; 32(6):354. PubMed ID: 38750379
[TBL] [Abstract] [Full Text] [Related]
12. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
13. Perioperative Nivolumab in Resectable lung cancer.
Cascone T; Awad MM; Spicer JD; He J; Lu S; Sepesi B; Tanaka F; Taube JM; Cornelissen R; Havel L; Karaseva N; Kuzdzal J; Petruzelka LB; Wu L; Pujol JL; Ito H; Ciuleanu TE; de Oliveira Muniz Koch L; Janssens A; Alexandru A; Bohnet S; Moiseyenko FV; Gao Y; Watanabe Y; Coronado Erdmann C; Sathyanarayana P; Meadows-Shropshire S; Blum SI; Provencio Pulla M;
N Engl J Med; 2024 May; 390(19):1756-1769. PubMed ID: 38749033
[TBL] [Abstract] [Full Text] [Related]
14. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract] [Full Text] [Related]
15. Smoking, mortality, access to diagnosis, and treatment of lung cancer in Brazil.
Campos MR; Rodrigues JM; Marques AP; Faria LV; Valerio TS; Silva MJSD; Pires DC; Chaves LA; Cardoso CHD; Campos SR; Emmerick ICM
Rev Saude Publica; 2024; 58():18. PubMed ID: 38747866
[TBL] [Abstract] [Full Text] [Related]
16. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
Liang X; Xiao H; Li H; Chen X; Li Y
Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
[TBL] [Abstract] [Full Text] [Related]
17. Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.
Scotté F; Artru P; Saghatchian M; Chouaid C
Support Care Cancer; 2024 May; 32(6):347. PubMed ID: 38743147
[TBL] [Abstract] [Full Text] [Related]
18. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
Wang Y; Lu BH; Gao Y; Liu YX; Hu MM; Che NY; Lin HF; Li HX; Zhang HM; Zhang TM
Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):419-427. PubMed ID: 38742355
[No Abstract] [Full Text] [Related]
19. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
[No Abstract] [Full Text] [Related]
20. First in vitro measurement of VHEE relative biological effectiveness (RBE) in lung and prostate cancer cells using the ARES linac at DESY.
Wanstall HC; Burkart F; Dinter H; Kellermeier M; Kuropka W; Mayet F; Vinatier T; Santina E; Chadwick AL; Merchant MJ; Henthorn NT; Köpke M; Stacey B; Jaster-Merz S; Jones RM
Sci Rep; 2024 May; 14(1):10957. PubMed ID: 38740830
[TBL] [Abstract] [Full Text] [Related]
[Next]
